APA (7th ed.) Citation

Kotaka, M., Xu, R., Muro, K., Park, Y. S., Morita, S., Iwasa, S., . . . Kim, T. W. (2016). Study protocol of the Asian XELIRI ProjecT (AXEPT): A multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. BMC.

Chicago Style (17th ed.) Citation

Kotaka, Masahito, et al. Study Protocol of the Asian XELIRI ProjecT (AXEPT): A Multinational, Randomized, Non-inferiority, Phase III Trial of Second-line Chemotherapy for Metastatic Colorectal Cancer, Comparing the Efficacy and Safety of XELIRI with or Without Bevacizumab Versus FOLFIRI with or Without Bevacizumab. BMC, 2016.

MLA (9th ed.) Citation

Kotaka, Masahito, et al. Study Protocol of the Asian XELIRI ProjecT (AXEPT): A Multinational, Randomized, Non-inferiority, Phase III Trial of Second-line Chemotherapy for Metastatic Colorectal Cancer, Comparing the Efficacy and Safety of XELIRI with or Without Bevacizumab Versus FOLFIRI with or Without Bevacizumab. BMC, 2016.